Pancreatic ductal adenocarcinoma (PDAC) is one of the most common causes of cancer related death. Despite the advances in understanding of the molecular pathogenesis, pancreatic cancer remains a major unsolved health problem. Overall, the 5-year survival rate is less than 5% demonstrating the insufficiency of current therapies. Most cytotoxic therapies induce apoptosis and PDAC cells have evolved a plethora of molecular mechanisms to assure survival. We will present anti-apoptotic strategies working at the level of the death receptors, the mitochondria or involving the caspase inhibitors of the IAP family. Furthermore, the survival function of the phosphotidylinositol-3′ kinase (PI3K)/AKT- and NF-kappaB-pathways are illustrated. A detailed molecular knowledge of the anti-apoptotic mechanisms of PDAC cells will help to improve therapies for this dismal disease and therapeutic strategies targeting the programmed cell death machinery are in early preclinical and clinical development. © 2008 Hamacher et al; licensee BioMed Central Ltd.
CITATION STYLE
Hamacher, R., Schmid, R. M., Saur, D., & Schneider, G. (2008, July 24). Apoptotic pathways in pancreatic ductal adenocarcinoma. Molecular Cancer. https://doi.org/10.1186/1476-4598-7-64
Mendeley helps you to discover research relevant for your work.